Status:

COMPLETED

Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (EU Extension Study)

Lead Sponsor:

CSL Behring

Conditions:

Primary Immunodeficiency (PID)

Eligibility:

All Genders

2-65 years

Phase:

PHASE3

Brief Summary

This study is a continuation of the study ZLB06\_001CR with the objective of assessing efficacy, tolerability, safety of IgPro, as well as long-term health-related quality of life in patients with PID...

Eligibility Criteria

Inclusion

  • Subjects with primary humoral immunodeficiency, namely with a diagnosis of Common variable immunodeficiency (CVID) as defined by the Pan-American Group for Immunodeficiency (PAGID) and the European Society for Immunodeficiencies (ESID), or X-linked agammaglobulinemia (XLA) as defined by PAGID and ESID, or autosomal recessive agammaglobulinemia who have participated in the study ZLB06\_001CR and who have tolerated IgPro well
  • Written informed consent

Exclusion

  • Hypoalbuminemia, protein-losing enteropathies, and any proteinuria (defined as total urine protein concentration \> 0.2g/L)
  • Other significant medical conditions that could increase the risk to the subject
  • Females who are pregnant, breast feeding or planning a pregnancy during the course of the study
  • Participation in a study with an investigational medicinal product within three months prior to enrollment, except for ZLB06\_001CR
  • Evidence of uncooperative attitude
  • Any condition that is likely to interfere with evaluation of the IMP or satisfactory conduct of the study
  • Subjects who are employees at the investigational site, relatives or spouse of the investigator

Key Trial Info

Start Date :

August 1 2008

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 1 2011

Estimated Enrollment :

40 Patients enrolled

Trial Details

Trial ID

NCT00751621

Start Date

August 1 2008

End Date

December 1 2011

Last Update

April 2 2014

Active Locations (13)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 4 (13 locations)

1

Study Site

Paris, France, 75743

2

Study Site

Berlin, Germany, 13353

3

Study Site

Freiburg im Breisgau, Germany, 79095

4

Study Site

Leipzig, Germany, 04129